Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010

Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010

Show other versions (1)

Interferon-α based therapy for chronic hepatitis C (CHC) is associated with thyroiditis and thyroid dysfunction (TD). This study investigated whether TD during pegylated interferon-α (PEG-IFN) plus ribavirin treatment favors sustained viral response (SVR), and also the association between TD and PEG...

Full description

Bibliographic Details
Main Authors:	Sener Barut, Ozgur Gunal, Unal Erkorkmaz, Feyza Yildiz
Format:	Article
Language:	English
Published:	Elsevier 2012-09-01
Series:	Brazilian Journal of Infectious Diseases
Online Access:	http://www.sciencedirect.com/science/article/pii/S1413867012001316

Similar Items

Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010
by: Sener Barut, et al.

Side Effects of Therapy for Chronic Hepatitis C: High Incidence of Dermal and Mucosal Adverse Events
by: Hüseyin Şener BARUT, et al.
Published: (2010-03-01)

Efficacy of daclatasvir plus peginterferon alfa and ribavirin for patients with chronic hepatitis C genotype 4 infection
by: Hussien Ahmed, et al.
Published: (2017-03-01)

Long-term histological change in chronic hepatitis C patients who had received peginterferon plus ribavirin therapy with sustained virological response
by: Chia-Ying Chu, et al.
Published: (2019-07-01)

Individualizing HCV treatment with peginterferon and ribavirin: what needs to be done?
by: Donald M. Jensen
Published: (2009-01-01)

Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin
by: Guillermo Cabrera Álvarez, et al.
Published: (2011-10-01)

Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan
by: Jung-An Lin, et al.
Published: (2014-10-01)

Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin
by: Osamu Yokosuka, et al.
Published: (2012-08-01)

Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy
by: E. Parise, et al.

Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
by: Young Kul Jung, et al.
Published: (2013-03-01)

Chronic HCV treatment with peginterferon-ribavirin and severe tuberculosis re-activation
by: Calza Leonardo, et al.
Published: (2010-05-01)

Increased baseline proinflammatory cytokine production in chronic hepatitis C patients with rapid virological response to peginterferon plus ribavirin.
by: Gabriella Par, et al.
Published: (2013-01-01)

Association of vitamin D receptor gene polymorphisms with response to peginterferon plus ribavirin in Asian patients with chronic hepatitis C
by: Chao-Hung Hung, et al.
Published: (2016-04-01)

Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin.
by: Alex Thompson, et al.
Published: (2014-01-01)

Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea
by: Suh Yoon Yang, et al.
Published: (2015-06-01)

Psychosis during peginterferon-alpha2a and ribavirin therapy: case report
by: Lucas C. Quarantini, et al.

Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis
by: O&#39;Regan C, et al.
Published: (2012-02-01)

A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin
by: Ching-Sheng Hsu, et al.
Published: (2014-10-01)

Association of genetic variations in <it>GNB1</it> with response to peginterferon plus ribavirin therapy for chronic hepatitis C in a Chinese population in Taiwan
by: Lim Yun-Ping, et al.
Published: (2012-11-01)

Chronic Hepatitis C treatment for genotype 2 or 3 in Brazil: cost effectiveness analysis of peginterferon plus ribavirin as first choice treatment
by: Carine Raquel Blatt, et al.
Published: (2014-04-01)

No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients
by: Nae-Yun Heo, et al.
Published: (2014-06-01)

The Predictive Factors for Favorable Outcomes of Peginterferon and Ribavirin Combination Therapy in HCV-Infected Patients
by: Javad Moayedi, et al.
Published: (2020-08-01)

Mycobacterium abscessus pulmonary infection during hepatitis C treatment with telaprevir, peginterferon and ribavirin
by: Alejandro Soza, M.D., et al.
Published: (2015-01-01)

Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial
by: Mario G. Pessôa, et al.
Published: (2012-01-01)

Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study
by: Ide K, et al.
Published: (2016-03-01)

Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study.
by: Wolf Peter Hofmann, et al.
Published: (2015-01-01)

Peginterferon Alfa-2a plus Ribavirin in Japanese Patients Infected with Hepatitis C Virus Genotype 2 Who Failed Previous Interferon Therapy
by: Tatsuo Kanda, Shingo Nakamoto, Takayoshi Nishino, Nobuo Takada, Akihito Tsubota, Keizo Kato, Tatsuo Miyamura, Daisuke Maruoka, Shuang Wu, Takeshi Tanaka, Makoto Arai, Shigeru Mikami, Keiichi Fujiwara, Fumio Imazeki, Osamu Yokosuka
Published: (2013-01-01)

Ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin in treatment-experienced patients with chronic hepatitis C virus genotype 1 infection
by: Bernstein D, et al.
Published: (2019-02-01)

Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan
by: Meng-Hsuan Hsieh, et al.
Published: (2018-06-01)

SVR12 is higher than SVR24 in treatment-naïve hepatitis C genotype 1 patients treated with peginterferon plus ribavirin
by: Thorlund K, et al.
Published: (2014-01-01)

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C.
by: Robert Flisiak, et al.
Published: (2016-01-01)

Superiority of peginterferon α-2a and ribavirin combination over peginterferon α-2a monotherapy in the management of hemodialysis patients with chronic Hepatitis C virus infection
by: Saeed M.G Al-Ghamdi, et al.
Published: (2017-01-01)

Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia
by: Božić Milena, et al.
Published: (2012-01-01)

Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil
by: Marcelo Cunio Machado Fonseca, et al.

Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C
by: Seok Hoo Jeong, et al.
Published: (2012-12-01)

Interleukin-28B (rs12979860) gene variation and treatment outcome after peginterferon plus ribavirin therapy in patients with genotype 1 of hepatitis C virus
by: Hamid Kalantari, et al.
Published: (2014-01-01)

Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings
by: Cheng-Pin Chen, et al.
Published: (2019-08-01)

Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial
by: Francisco Bosques-Padilla, MD, et al.
Published: (2003-07-01)

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1).
by: Tarik Asselah, et al.
Published: (2016-01-01)

Adverse Effects of Two Different Peginterferon Molecules with Ribavirin Combination Therapy Used To Treat Chronic Hepatitis C
by: Saygın NAYMAN ALPAT, et al.
Published: (2008-06-01)